Muscarinic Receptors and Alzheimer's Disease: New Perspectives and Mechanisms

被引:2
|
作者
Monaco, Martina [1 ]
Trebesova, Hanna [1 ]
Grilli, Massimo [1 ,2 ]
机构
[1] Univ Genoa, Dept Pharm, Viale Cembrano 4, I-16148 Genoa, Italy
[2] Interuniv Ctr Promot 3Rs Principles Teaching & Res, I-16148 Genoa, Italy
关键词
Alzheimer's disease; muscarinic receptors; cholinergic transmission; neuroinflammation; innovative therapy; ACETYLCHOLINE-RECEPTOR; BINDING; DEFICITS; AGONIST; MEMORY; MODEL; NEUROINFLAMMATION; EXPRESSION; AROUSAL; PROTEIN;
D O I
10.3390/cimb46070407
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases on a global scale. Historically, this pathology has been linked to cholinergic transmission, and despite the scarcity of effective therapies, numerous alternative processes and targets have been proposed as potential avenues for comprehending this complex illness. Nevertheless, the fundamental pathophysiological mechanisms underpinning AD remain largely enigmatic, with a growing body of evidence advocating for the significance of muscarinic receptors in modulating the brain's capacity to adapt and generate new memories. This review summarizes the current state of the art in the field of muscarinic receptors' involvement in AD. A specific key factor was the relationship between comorbidity and the emergence of new mechanisms.
引用
收藏
页码:6820 / 6835
页数:16
相关论文
共 50 条
  • [41] The utility of muscarinic agonists in the treatment of alzheimer’s disease
    William S. Messer
    Journal of Molecular Neuroscience, 2002, 19 : 187 - 193
  • [42] Potential role of muscarinic agonists in Alzheimer's disease
    Avery, EE
    Baker, LD
    Asthana, S
    DRUGS & AGING, 1997, 11 (06) : 450 - 459
  • [43] The utility of muscarinic agonists in the treatment of Alzheimer's disease
    Messer, WS
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 19 (1-2) : 187 - 193
  • [44] Potential Role of Muscarinic Agonists in Alzheimer’s Disease
    Eleanor E. Avery
    Laura D. Baker
    Sanjay Asthana
    Drugs & Aging, 1997, 11 : 450 - 459
  • [45] Muscarinic partial agonists in the treatment of Alzheimer's disease
    Loudon, JM
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P384 - P384
  • [46] Muscarinic agonists and antagonists in the treatment of Alzheimer's disease
    Greenlee, W
    Clader, J
    Asberom, T
    McCombie, S
    Ford, J
    Guzik, H
    Kozlowski, J
    Li, S
    Liu, C
    Lowe, D
    Vice, S
    Zhao, H
    Zhou, G
    Billard, W
    Binch, H
    Crosby, R
    Duffy, R
    Lachowicz, J
    Coffin, V
    Watkins, R
    Ruperto, V
    Strader, C
    Taylor, L
    Cox, K
    FARMACO, 2001, 56 (04): : 247 - 250
  • [47] M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease - Rationale and perspectives
    Fisher, A
    Michaelson, DM
    Brandeis, R
    Haring, R
    Chapman, S
    Pittel, Z
    MOLECULAR BASIS OF DEMENTIA, 2000, 920 : 315 - 320
  • [48] M1 muscarinic agonists as a therapeutic strategy in Alzheimer's disease - M1 muscarinic agonists in Alzheimer's disease
    Fisher, A
    Pittel, Z
    Haring, R
    Brandeis, R
    Bar-Ner, N
    Sonego, H
    Marcovitch, I
    Natan, N
    Mestre-Frances, N
    Bons, N
    MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 205 - 210
  • [49] Neurotrophin receptors in Alzheimer's disease
    Salehi, A
    Verhaagen, J
    Swaab, DF
    NEURONAL DEGENERATION AND REGENERATION: FROM BASIC MECHANISMS TO PROSPECTS FOR THERAPY, 1998, 117 : 71 - 89
  • [50] Lipoprotein receptors in Alzheimer's disease
    Andersen, Olav M.
    Willnow, Thomas E.
    TRENDS IN NEUROSCIENCES, 2006, 29 (12) : 687 - 694